BriaCell Therapeutics Corp. 8-K

What Happened
BriaCell Therapeutics Corp. (BCTX) announced that it entered an asset purchase agreement with its majority-owned subsidiary, BriaPro Therapeutics Corp., under which BriaPro will acquire BriaCell’s exclusive license to develop and commercialize Soluble CD80 for cancer treatment and certain related assets. As consideration, BriaPro will issue 23,972,589 common shares to BriaCell, raising BriaCell’s ownership in BriaPro to approximately 78%. The company also agreed to make up to $3.0 million available to BriaPro through a credit facility to support research and development, with each drawdown subject to BriaCell’s approval. The transaction is expected to close on or about March 12, 2026, subject to customary conditions including approval by disinterested BriaPro shareholders and an independent third‑party valuation. A press release dated February 18, 2026 is attached as Exhibit 99.1.

Key Details

• BriaPro will acquire the exclusive license for Soluble CD80 (a therapeutic candidate for cancer) and related assets.
• Consideration: 23,972,589 BriaPro common shares issued to BriaCell, increasing BriaCell’s stake to ~78%.
• Financing support: Up to $3.0 million available under a BriaCell-approved credit facility for R&D drawdowns.
• Timing & conditions: Expected close on or about March 12, 2026; requires disinterested shareholder approval and an independent valuation.

Why It Matters
The deal shifts ownership and operational control of the Soluble CD80 program into BriaPro while keeping BriaCell as the majority holder, which could concentrate development activity in the subsidiary and align financing to that effort. Investors should note the change in where the Soluble CD80 asset will be developed, the dilution/ownership update (BriaCell at ~78% of BriaPro post-transaction), the potential funding commitment of up to $3.0 million, and that closing depends on shareholder approval and a third‑party valuation. The filing is informational about corporate structure and asset allocation rather than new clinical results or financial earnings.